CXCL10 antibody (Biotin)

Catalog No. ABIN2661156

Product Details anti-CXCL10 Antibody (Biotin)

Target: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Reactivity: Human

Host: Goat

Clonality: Polyclonal

Conjugate: This CXCL10 antibody is conjugated to Biotin

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Clone: Poly5194

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CXCL10

Target: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Alternative Name: CXCL10 (CXCL10 Products)

Synonyms: CXCL10 antibody, C7 antibody, IFI10 antibody, INP10 antibody, IP-10 antibody, SCYB10 antibody, crg-2 antibody, gIP-10 antibody, mob-1 antibody, CRG-2 antibody, IP10 antibody, Ifi10 antibody, Scyb10 antibody, C-X-C motif chemokine ligand 10 antibody, C-X-C motif chemokine 10 antibody, chemokine (C-X-C motif) ligand 10 antibody, CXCL10 antibody, cxl10 antibody, Cxcl10 antibody

Background: CXCL10 is an ELR-negative chemokine structurally and functionally related to CXCL9 and CXCL11. CXCL10, CXCL9, and CXCL11 are produced and secreted by monocytes, macrophages, fibroblasts, and epithelial cells upon stimulation with proinflammatory cytokines, especially IFNγ. CXCL10 chemoattracts CD4, CD8, and NK and NKT cells through the binding to its receptor CXCR3, which is shared with CXCL9 and CXCL11. In addition, CXCL10 inhibits neovascularization in tumors and in wound healing in vivo. Also, CXCL10 has anti-proliferative effects on endothelial cells in vitro, and angiostatic and antitumor effects in vivo. It has been suggested that the anti-proliferative effect of CXCL10 in endothelial cells is CXCR3-independent and that it is mediated through GAG interaction. CXCL10 also possesses antimicrobial activity against E. coli and L. monocytogenes, and both the spore and bacillus forms of B. anthracis. CXCL10 expression is strongly upregulated in many human inflammatory diseases, including rheumatoid arthritis, type I diabetes, multiple sclerosis, atherosclerosis, allograft rejection, and others.